BiomX Inc. (PHGE)

NYSEAMERICAN: PHGE · Real-Time Price · USD
0.3958
-0.0022 (-0.55%)
Jul 18, 2025, 4:00 PM - Market closed
-0.55%
Market Cap10.36M
Revenue (ttm)n/a
Net Income (ttm)-8.06M
Shares Out 26.18M
EPS (ttm)-2.13
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume474,901
Open0.4000
Previous Close0.3980
Day's Range0.3870 - 0.4050
52-Week Range0.3400 - 3.4800
Beta1.42
AnalystsStrong Buy
Price Target15.00 (+3,689.79%)
Earnings DateAug 13, 2025

About PHGE

BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. It also developing BX004, a phage therapy for cystic fibrosis and non-cystic fibrosis bronchiectasis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clini... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 57
Stock Exchange NYSEAMERICAN
Ticker Symbol PHGE
Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to one analyst, the rating for PHGE stock is "Strong Buy" and the 12-month stock price target is $15.0.

Price Target
$15.0
(3,689.79% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

BiomX Announces Successful Initiation of Phase 2b Trial with First Patient Dosed in BX004 Program in Patients with Cystic Fibrosis

First patient dosing in Company's Phase 2b trial marks pivotal milestone in phage therapy development program targeting antibiotic-resistant lung infections in Cystic Fibrosis patients; topline result...

5 days ago - GlobeNewsWire

BiomX Announces Publication in Nature Communications of Phage Cocktail BX004 Phase 1b/2a Part 1 Data Demonstrating Strong Activity in Cystic Fibrosis

Premier research journal article provides validation for BiomX's phage therapy platform, showcasing first-in-human Phase 1b/2a trial results for antibiotic-resistant P. aeruginosa infections New, upda...

11 days ago - GlobeNewsWire

BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference

Presentation to Focus on Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO) Presentation to Focus on Positive Topline Results from Phas...

2 months ago - GlobeNewsWire

BiomX Inc. (PHGE) Q1 2025 Earnings Conference Call Transcript

BiomX Inc. (NYSE:PHGE) Q1 2025 Earnings Conference Call May 15, 2025 2:00 PM ET Company Participants Marina Wolfson - CFO Jonathan Solomon - CEO Conference Call Participants Joe Pantginis - H.C. Wain...

2 months ago - Seeking Alpha

BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates

In March 2025, BiomX announced positive topline results of the phase 2 trial evaluating BX211 for the treatment of diabetic foot osteomyelitis (DFO)

2 months ago - GlobeNewsWire

BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025

NESS ZIONA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that t...

2 months ago - GlobeNewsWire

BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure

NESS ZIONA, Israel, April 01, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that...

3 months ago - GlobeNewsWire

BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)

The Company will host a conference call and webcast today at 9:00 AM ET, followed by a Key Opinion Leader (KOL) event on April 3, 2025, at 11:00 AM ET to discuss the results

3 months ago - GlobeNewsWire

BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates

NESS ZIONA, Israel, March 25, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE, the “Company” or “BiomX”), a clinical-stage company advancing novel natural and engineered phage therapies that ...

4 months ago - GlobeNewsWire

BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

NESS ZIONA, Israel, March 19, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that...

4 months ago - GlobeNewsWire

BiomX Inc. (PHGE) Q3 2024 Earnings Call Transcript

BiomX Inc. (NYSE:PHGE) Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ET Company Participants Marina Wolfson – Chief Financial Officer Jonathan Solomon – Chief Executive Officer Conferenc...

8 months ago - Seeking Alpha

BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates

BX211 Phase 2 for treatment of Diabetic Foot Osteomyelitis (DFO) patient enrollment completed and on track to report topline results in Q1 2025

8 months ago - GlobeNewsWire

BiomX to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 14, 2024

NESS ZIONA, Israel, Nov. 12, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that ...

8 months ago - GlobeNewsWire

BiomX Announces a Mandatory Unit Separation

GAITHERSBURG, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that t...

9 months ago - GlobeNewsWire

BiomX to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis Conference

GAITHERSBURG, Md., Sept. 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that ...

10 months ago - GlobeNewsWire

BiomX to Present at the H.C. Wainwright 26th Annual Global Investment Conference

GAITHERSBURG, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that ...

11 months ago - GlobeNewsWire

UPDATE ON UNITS - BiomX Inc. Announces 1-for-10 Reverse Stock Split

In a release issued under the same headline yesterday by BiomX (NYSE American: PHGE), the third and fourth paragraphs have been updated to include information regarding adjustment of outstanding units...

1 year ago - GlobeNewsWire

BiomX Inc. (PHGE) Q2 2024 Earnings Call Transcript

BiomX Inc. (NYSE:PHGE) Q2 2024 Earnings Call Transcript August 15, 2024 8:00 AM ET Company Participants Marina Wolfson - CFO Jonathan Solomon - CEO Conference Call Participants Yale Jen - Laidlaw & C...

1 year ago - Seeking Alpha

BiomX Inc. Announces 1-for-10 Reverse Stock Split

GAITHERSBURG, Md., Aug. 15, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that t...

1 year ago - GlobeNewsWire

BiomX Reports Second Quarter 2024 Financial Results and Provides Business and Program Updates

BiomX anticipates reporting important results in 2025 for two clinical assets from the Company's leading pha ge therap y pipeline

1 year ago - GlobeNewsWire

BiomX to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 15, 2024

GAITHERSBURG, Md., Aug. 08, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that t...

1 year ago - GlobeNewsWire

Top 3 Health Care Stocks That May Explode In Q3

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. `

Other symbols: DXCMEW
1 year ago - Benzinga

BiomX Inc. Announces NYSE American Acceptance of Plan to Regain Listing Compliance

GAITHERSBURG, Md., July 29, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that t...

1 year ago - GlobeNewsWire

BiomX Inc. Announces Stockholder Approval for Conversion of Outstanding Series X Convertible Preferred Stock to Common Stock

GAITHERSBURG, Md., July 10, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that t...

1 year ago - GlobeNewsWire

BiomX Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

GAITHERSBURG, Md. and NESS ZIONA, Israel, May 30, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered ...

1 year ago - GlobeNewsWire